Clinical trials: Movement Abnormalities
Essential Tremor, Parkinson's Disease
Evaluation of the Infinity Deep Brain Stimulation Electrode Screening Mode Tool
The objective of this clinical investigation is to characterize the clinical performance of Abbott's Clinician Programmer Electrode Screening Mode tool (InformityTM tool) in programming InfinityTM deep brain stimulation (DBS)…
- Trial name
- EVIDENT (NCT03794661)
- Testing
- Clinician programmer electrode screening mode tool
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Abbott Medical Devices
Parkinson's Disease
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
- Trial name
- NCT00292227
- Testing
- Rotigotine, Moxifloxacin infusion
- Where
- 2 sites in South Africa
- Volunteers
- 130 people
- Sponsor
- UCB Pharma
Parkinson's Disease, Motor Symptoms
Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®
To determine if PT intervention will be improved while in the "on" motor state vs. the "end-of-dose-off" motor state during the PT Intervention Visit in subjects with PD.
- Trial name
- PERFORM (NCT02549573)
- Testing
- APOKYN, Physical Therapy
- Where
- 12 sites in United States
- Volunteers
- 13 people
- Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Parkinson's Disease
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms
The objective of this trial is to evaluate safety and efficacy of rotigotine nasal spray (SPM 952) in a single dose application scheme.
- Trial name
- NCT00296192
- Testing
- Rotigotine nasal spray
- Volunteers
- 82 people
- Sponsor
- UCB Pharma
Parkinson Disease
Effects of Exercise Training and Ketone Ester on Muscle Strength and Cardiovascular Response in Parkinson's Disease
The main purpose of this study is to assess changes in exercise capacity in people with Parkinson's disease before and after an exercise training program with ketone ester supplementation.
- Trial name
- CYCLE (NCT05948956)
- Testing
- Ketone Ester Beverage, Electrolyte Beverage, Cycling Intervention
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide
To investigate the effect of three single oral doses of BIA 9-1067 (25 mg, 50 mg and 100 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled-release levodopa 100 mg/benserazide…
- Trial name
- NCT02169466
- Testing
- BIA 9-1067, Madopar® HBS
- Where
- Portugal
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease.
- Trial name
- NCT05036473
- Testing
- WD-1603 Carbidopa-Levodopa Extended-Release Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai WD Pharmaceutical Co., Ltd.
Parkinson Disease, Dyskinesia, Drug-Induced
Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors
In this study, the investigators will examine the association of statin use and dyskinesia in a convenience sample Parkinson's disease patients in the Veterans Administration Health Care System.
- Trial name
- STAT-PD (NCT04064294)
- Testing
- Intravenous Infusion
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Parkinson Disease
Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression
A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
- Trial name
- NCT01556100
- Testing
- 18F-DTBZ AV-133
- Volunteers
- 40 people
- Sponsor
- Chang Gung Memorial Hospital
Parkinson Disease
Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole
The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.
- Trial name
- NCT00615914
- Where
- 273 sites in Japan
- Volunteers
- 1,645 people
- Sponsor
- Boehringer Ingelheim
Huntington's Disease
A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
The purpose of the study is to collect and assess long term data on the safety, tolerability, and efficacy of pridopidine in patients with Huntington's disease (HD).
- Trial name
- Open PRIDE-HD (NCT02494778)
- Testing
- Pridopidine
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 248 people
- Sponsor
- Prilenia
Parkinson's Disease
Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal
A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Decarboxylase Inhibitor to L-dopa Responsive…
- Trial name
- THOR201 (NCT03541356)
- Testing
- L-dopa 35 mg, L-dopa 70mg, L-dopa 140 mg
- Where
- 5 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Impel Pharmaceuticals
Parkinson Disease
Feasibility and Effect of a Strategy-Based Cognitive Intervention for Parkinson Disease
Parkinson disease (PD) affects over 1 million Americans and causes considerable personal and socioeconomic costs (>$34 billion/year in the US) that are expected to rise as the population ages.
- Trial name
- NCT04048122
- Testing
- MultiContext for PD Strategy Training, Standard of Care
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Washington University School of Medicine
Parkinson's Disease
A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients
The primary objective of this study is to investigate safety of SPM 962 in advanced PD patients in a multi-center, open-label, non-controlled study following once-daily multiple transdermal doses of SPM962 within a range of 4.5…
- Trial name
- NCT01631812
- Testing
- SPM 962
- Where
- 7 sites in Japan
- Volunteers
- 130 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Parkinson Disease
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
The purpose of the study is to learn about the effect of GOCOVRI (Amantadine extended release) on activity levels and measures of gait and balance quality in people with Parkinson's disease (PD) and levodopa induced dyskinesia…
- Trial name
- NCT04387773
- Testing
- GOCOVRI
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Oregon Health and Science University
Focal Dystonia
Amlodipine Plus Botulinum Toxin for Focal Dystonia
Objective: To determine if the calcium channel blockers, amlodipine can augment the effect of botulinum toxin injections in the treatment of focal dystonia.
- Trial name
- NCT00015457
- Testing
- Amlodipine plus Botulinum toxin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Sialorrhea
Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects
This study will evaluate the efficacy and safety of MYOBLOC in the treatment of Sialorrhea (drooling), which can be a symptom of many disease conditions. MYOBLOC will be injected directly into the salivary glands.
- Trial name
- MYSTICOL (NCT01994109)
- Testing
- MYOBLOC
- Where
- 34 sites in United States, Russia and 1 more
- Volunteers
- 187 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Parkinson Disease
Low Frequency Subthalamic Nucleus Deep Brain Stimulation to Improve Verbal Fluency
Rationale: Parkinson's disease patients with deep brain stimulation electrodes represent a unique opportunity to study the influence of basal ganglia on neurocognitive function.
- Trial name
- NCT04383665
- Testing
- STN DBS 10Hz, STN DBS 130Hz, STN DBS off
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Southern California
Parkinson Disease
Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa
To investigate the pharmacokinetics of levodopa when administered concomitantly with BIA 9-1067 or 1 hour after.
- Trial name
- NCT01533077
- Testing
- BIA 9-1067, Sinemet® 100/25 mg
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.